Phase II data for Corixa's PVAC

CRXA said that in a U.S. Phase II trial of its PVAC M. vaccae immunotherapeutic in 241 patients with moderate to severe psoriasis, the product was well tolerated at a dose of 15 ug and reduced the pso...